Close

News

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA...

Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL

Cephalon, Inc.announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients...

First HIV diagnostic assay Results Available in Less Than 50 Minutes

Ortho Clinical Diagnostics announced U.S. FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.  This is...

Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc.

Bristol-Myers Squibb Company announced that it has completed its previously announced acquisition of ZymoGenetics, Inc.. As a result of the transaction, ZymoGenetics has become a wholly-owned subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb initiated on September 10,...

BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX for Treatment of Peyronie’s Disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first subject in the global Phase 3 program of XIAFLEX® (collagenase clostridium histolyticum) for the treatment...

AstraZeneca and PoZEN received approval for VIMOVO in Europe

AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets has cleared an important regulatory milestone by receiving positive agreement for approval in 23 countries across the European Union (EU). This follows all 22...

Bexion Pharmaceuticals Continues to Gain Support from National Cancer Institute (NCI)

Bexion Pharmaceuticals announced that it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI). The grant entitled “SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme” was awarded September 28, 2010 and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read